Navigation Links
Poniard Pharmaceuticals Announces Management Changes and Reduction in Force
Date:2/3/2010

_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='83452362';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.poniard.com/">http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements describing the Company's regulatory and partnering strategies with respect to its picoplatin product candidate and the expected cost savings and other benefits related to the reduction in force. Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties inherent in the Company's business, including, but not limited to, the results and timing of the Company's discussions with the FDA; the potential safety, efficacy and commercial viability of picoplatin; the risk that the Company's additional analyses of data from clinical trials of picoplatin may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted trials; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; the Company's ability to retain key personnel and enter into strategic partnerships on favorable terms, or at all; competition from third parties; the Company's ability to preserve and protect its intellectual property rights; the Company's dependence on third-party manufacturers, suppliers and other contractors; changes in technology, government regulation and general market conditions; the receipt and timing of any FDA and other required regulatory approvals, if any; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and its Quarterly Report on Form 10-Q
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
2. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
3. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
4. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
6. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
7. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
8. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
9. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
10. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
11. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 /CNW/ -   ... after Health Canada tests confirmed it contains two undeclared ... and phenylpropylmethylamine). The distributor, Empire Health Distribution of ... from retail stores across Canada . ... for weight loss and increased energy. ...
(Date:12/24/2014)... , Dec. 24, 2014  Novastem, a ... its first patient in its study for ischemic ... American Stroke Association, ischemic strokes account for 87 ... enroll qualified patients in the study, entitled "Internal ... of Allogeneic Mesenchymal Stem Cells and Intrathecal Administration ...
(Date:12/24/2014)... Dec. 24, 2014  Actavis plc (NYSE: ... has received a complete response letter from the ... New Drug Application (NDA) for the fixed-dose combination ... of hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... in the receipt of a complete response letter, ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... One of the more difficult aspects of planning ... resource and investment allocations that are needed to prepare ... wrestle with allocating the appropriate resources for informing key ... are carried out across different functional areas. ...
... Floridians turned in nearly 5,500 pounds of prescription and ... enforcement offices throughout the state during the Drug Take ... the amount dropped off at 38 sites last year. ... National Association of Drug Diversion Investigators (NADDI) ...
Cached Medicine Technology:Study Uncovers Key Success Factors and Common Failure Points for Launching New Metabolic Products in Today's Competitive Healthcare Market 2NADDI and the C.A.R.E.S. Alliance Co-Sponsor Successful Drug Take Back Day 2
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... 26, 2014 This is a professional ... global Sterilizers industry with a focus on the Chinese ... status of the Sterilizers manufacturers and is a valuable ... interested in the industry. This report provides a basic ... manufacturing technology. In this part, the report presents the ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... Previous studies have shown that hepatitis C virus (HCV) ... than in whites. However, researchers demonstrate in this study, ... the American Association for the Study of Liver Diseases, ... recurrent HCV in the transplanted liver progresses faster in ...
... particular risk of their primary care physicians delaying diagnosis ... being presented at the American Society of Nephrology,s 42nd ... The findings suggest that educating practitioners about CKD ... to improvements in care to patients and savings in ...
... ,One Million Tests, World AIDS Day 2008 Campaign, AHF/Cambodia CARES ... 35,034 , PHNOM PENH, Cambodia, Oct. 31 As ... people for HIV in observance of the Testing ... will launch its inaugural testing effort during the annual Water ...
... suggests mortality rate may be linked to health-care inadequacies ... dementia are diagnosed with flu less often, have shorter ... die than those without dementia, says a U.S. study ... and older. , "The increased mortality of older patients ...
... , SAN FRANCISCO, Oct. 30 House speaker Nancy Pelosi ... Brown & Toland and a growing coalition of community groups ... epidemic. , Hepatitis B can cause liver cancer and ... Free campaign, of which Brown & Toland is a part, ...
... ... , ... 30, 2009 -- On Thursday this week, House Democratic leaders presented a new health care ... series of changes to accommodate lawmakers, concerns. In the Senate, Majority Leader Harry Reid (D-Nev.) ...
Cached Medicine News:Health News:African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C 2Health News:African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C 3Health News:Women with chronic kidney disease more likely than men to go undiagnosed 2Health News:Cambodia: World AIDS Day HIV Campaign, 'Testing Millions,' to Again Launch During Cambodia's National Water Festival 2Health News:Flu Deaths Higher Among Seniors With Dementia 2Health News:Brown & Toland Supports Fight Against Hepatitis B 2Health News:NAMI Applauds Initial Review of The Affordable Health Care of America Act and Health Care Reform 2Health News:NAMI Applauds Initial Review of The Affordable Health Care of America Act and Health Care Reform 3
Permits rotation of the globe during examination. Overall length,123mm....
... Centuries of German Craftsmanship ... surgical instrumentation in the ... them available to you! ... coveted Meisterbrief certificate, which ...
... Ophthalmic Products provide the ... free products for unparalleled ... cleaning of fine microsurgical ... material is highly absorbent, ...
... are constructed of a patented ... polyvinyl acetal sponge. Each device ... to both surgeon and patient, ... firm enough to gently manipulate ...
Medicine Products: